



Assembly Biosciences, Inc.  
Investor Relations Department  
787 7th Avenue 48th Floor  
New York, NY 10019  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

NASDAQ: ASMB	
Last Trade:	25.35
Trade Time:	4:00 PM ET May 24, 2017
Change:	1.25  (+5.187%)
Day Range	23.64 - 25.76
52-Week Range	5.00 - 28.18
Volume	37,652

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Assembly Biosciences, Inc. (Nasdaq: ASMB) is a public biotechnology company advancing a new class of oral biologic drugs for addressing the gut microbiome and novel approaches to discovering drugs for the treatment of hepatitis B virus (HBV) infection.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Feb 21, 2017*  
[Assembly Biosciences Announces the Closing and Early Termination of Hart-Scott-Rodino Waiting Period for License of Microbiome Gastrointestinal Development Programs to Allergan](#)
- Feb 16, 2017*  
[Assembly Biosciences Announces Successful Completion of ABI-H0731 Phase 1a Trial and Upcoming Conference Presentations](#)
- Jan 9, 2017*  
[Allergan Enters Into Licensing Agreement with Assembly Biosciences to Obtain Worldwide Rights to Microbiome Gastrointestinal Development Programs](#)
- Nov 11, 2016*  
[Assembly Biosciences to Present Data on ABI-H0731 at AASLD 2016 Liver Meeting](#)
- Nov 9, 2016*  
[Assembly Biosciences Initiates Phase 1 Clinical Program of ABI-H0731 for Treatment of Chronic Hepatitis B Virus Infection](#)

## Upcoming Events [\[ View all \]](#)

- Jun 7, 2017 10:00 AM ET*  
[Jefferies 2017 Global Healthcare Conference](#)
- Financials** [\[ View all \]](#)
  - [Third Quarter Financial Results](#)
- Mar 2, 2017*  
[Annual Report \(10-K\)](#)
- Apr 21, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- May 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2016*  
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2016*  
[Quarterly Report \(10-Q\)](#)